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ABSTRACT 
 Cancer genomics, in the context of informing clinical decisions with tumor genotype, is a 
field characterized by high-dimensional data. Computational approaches for evaluating sets of 
features to be utilized in machine learning methods are essential for yielding accurate predictive 
and prognostic models. Additionally, the publicly-available results of the Broad Institute’s 
Firehose cancer genomics analysis pipeline presents a wealth of information that may be useful 
for cancer genotyping. Power analysis and classifier comparison are performed with the goal of 
evaluating a gene-based mutation significance feature set (MutSig) from Firehose. They reveal 
that while the MutSig features likely contain some prognostic information, the methods with 
which they are currently integrated do not provide enough predictive power to result in 
clinically-useful decision support. Results also suggest that Random Forest or other bagged 
classifiers are potential good candidates for feature selection and model building in this context.  
 
INTRODUCTION AND BACKGROUND 
Head and Neck Cancer 
Cancer is a class of diseases characterized by abnormal cell growth and the potential for 
invasion of other tissues by cancerous cells. The cohort of cancer investigated in this thesis is 
Head and Neck Squamous Cell carcinoma (HNSC), including cancers of the oral cavity, 
pharynx, larynx, paranasal sinuses and nasal cavity, and salivary glands. Significant genetic 
alterations, or mutations, are necessary for cancer to develop. The effects of these mutations 
manifest as a combination of several traits: self-sufficient growth signals, insensitivity to anti-
growth signals, inhibition of apoptosis, rapid reproduction, continued angiogenesis, and cell 
migration (or metastasis). These traits cause the formation of malignant tumors, or masses of 
cancerous cells. 
Not all genetic alterations are created equally. Some mutations are more deleterious or 
cancer-causing, as different mutation locations and types can affect different biological pathways 
in a variety of manners. While molecular biomarkers and targeted sequencing are common in 
modern precision oncological medicine, the amount of genomic information that we do not know 
how to utilize is staggering. As a result, research broadly investigating these genotypic 
mechanisms is notoriously difficult, and limited success has been achieved incorporating 
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genotypes in clinical settings. To feasibly handle such large amounts of data, machine learning 
methods must be employed. 
TCGA and Broad Firehose 
 The data utilized in this thesis was generated by The Cancer Genome Atlas (TCGA) 
Network, a group dedicated to producing and analyzing genomic cancer data while making their 
data publicly available. TCGA has released genotyping, RNA and miRNA sequencing, whole 
exome sequencing, methylation, and clinical data for 528 cases of HNSC. Analysis of these data 
has revealed many genes previously unknown to be associated with HNSC.1 
 The Eli and Edythe L. Broad Institute of MIT and Harvard (or the Broad Institute) is a 
well-known bioinformatics research center. The Broad Institute’s Genomic Data Analysis Center 
(GDAC) has created a large analysis pipeline, Broad GDAC Firehose, to systematically analyze 
data from TCGA. The results of these analysis runs are published through online interactive 
figures through “Firebrowse”. One tool in this pipeline, MutSig2CV (or MutSig), analyzes 
exomic tumor-normal variant data. For each patient in the dataset, it identifies genes that are 
significantly mutated above an expected baseline and reports the most deleterious disruptions to 
those genes (See Figure 1).2,3 
 
Figure 1: The output of MutSig as viewed on Firebrowse.
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 Portion (a) contains the legend and a histogram, the 
former listing the different types of mutations identified and the latter displaying the number of patients found with 
each type of mutation in each gene. Genes are vertically sorted by mutation incidence. Portion (b) displays the 
MutSig output itself, with each column representing a single patient in the TCGA-HNSC dataset, sorted based on 
TP53 mutation, followed by FAT1 mutation, then CDKN2A mutation, and so on. 
 
Machine Learning 
 Machine learning (ML) is a computational field that uses algorithms to learn from 
existing data to discover relationships and build predictive models. Classification is a specific 
type of machine learning problem in which the algorithm is tasked with classifying data points 
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based on how previous data were classified. Essentially, data points consist of a set of features 
and a class label. A classifier is trained on the training data, and builds a predictive model to 
classify new data points. 
 To evaluate the effectiveness of a predictive model, it must be tested on data that it has 
not “seen” before. One standard, systematic way of doing this is called k-fold cross validation, 
where the available data is split into k partitions, or folds. Models are trained k times using k-1 of 
the folds as training data, while the remaining fold serves as the testing data. The performance of 
the classifier is then evaluated based on how it classified points in the testing data during the 
validation runs. 
 
 The primary goal of this research is to evaluate the Firehose MutSig2CV output in terms 
of how useful it might be in improving ML-based cancer outcome prediction. For this thesis, the 
outcome being predicted is defined as “two-year survival after diagnosis”. It is worth noting that 
this class label results in a skewed dataset, with 69.51% of patients in the TCGA data having a 




 Machine learning is becoming increasingly popular in cancer research, and multiple 
research groups are finding moderate success in this avenue.5,6,7 Some researchers still have 
reservations about some results, particularly with feature selection, as different studies do not 
always agree on what features are important for prediction.6 Nonetheless, a machine learning-
based approach appears to be the most promising path to deal with such complex, high-
dimensional data.8 
 Guo et al. describe a general procedure for applying machine learning to high-
dimensional “omics” data sets. It involves two primary steps: Dimensionality reduction and 
classifier training.9 In this thesis, the selection of the Firehose MutSig data serves as 
dimensionality reduction, and the evaluation experiments described in Methods fall under the 





 Machine Learning Classifiers 
Three types of machine learning classifiers were trained: Random Forest (RF), Multilayer 
Perceptron (MLP), and Glmnet.  
Random Forest is a “bagged” classifier—that is, it is a classifier consisting of a group of 
classifiers. Essentially, 100 decision tree classifiers are trained on the training data, the trees 
themselves choosing random features with which to discriminate between classes. The output 
predicted class is decided by a majority vote of the constituent trees. Bagged classifiers are 
known to be more effective for complicated problems, and Random Forest has been shown to be 
more effective when working with skewed datasets.9 
Multilayer Perceptron is a type of neural network, in this case having one input layer, one 
output layer, and 𝑎 =
𝑓+𝑐
2
  hidden layers, where f is the number of unique features in the training 
set, and c is the number of classes. Each node in the network uses a sigmoid kernel function. 
Glmnet is an algorithm that fits a generalized linear model via penalized maximum 
likelihood. In this case, the model built is a type of logistic regression model. It also utilizes lasso 
regularization, a regression analysis method that performs both regularization and feature 
selection to improve predictive accuracy.10,11 
The Random Forest and Multilayer Perceptron classifiers were trained and tested using 
their respective implementations in Weka 3.9.1, and Glmnet models were trained in Weka with 
the Glmnet R package through the RWeka interface. All classifiers used the default settings from 
their implementation and 10-fold cross validation unless otherwise noted. 
 Classifier Comparison Metrics 
 Three metrics were used to compare classifiers: accuracy, the area under the Receiver 
Operating Characteristic curve (AUROC), and the area under the Precision-Recall curve 
(AUPRC). While high accuracy is certainly desirable, it makes for a poor metric of predictive 
power. The Receiver Operating Characteristic (ROC) curve is a plot of true-positive rate versus 
false-positive rate while varying a discriminative threshold within the classifier. The area under 
this curve (AUROC, often denoted AUC) is a standard measure for predictive power in machine 
learning literature. The Precision-Recall curve is a plot of Precision versus Recall, and the area 
under this curve (AUPRC) is also a valuable measure of predictive power. Additionally, the 
AUPRC metric has been shown to be more discriminative in skewed datasets than AUROC 
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while being no less informative.12 Since this classification problem has prominent class 
imbalance, AUPRC was the primary consideration in model evaluation, followed by AUROC. 
Clinical-MutSig Evaluation 
 Classifiers were trained on 43 clinical data features, and then trained on a combination of 
the clinical data and 10 gene-based mutation significance (MutSig) features. The full list of 
clinical and mutation significance features used in this thesis can be found in Supplementary 
Tables 1 and 2, respectively. The description for Supplementary Table 2 also describes some 
feature selection and preprocessing of the mutation significance features. 
 Clinical-MutSig Power Evaluation 
 To examine the mutation significance data more directly, the mutation significance 
features were permuted by shuffling values randomly within each feature. These shuffled 
mutation significance features were then used with the actual non-shuffled clinical features to 
train the classifiers. A total of ten shuffled mutation significance datasets were created and used 
in this way. The mean and standard deviation of the predictive power metrics for these classifiers 
were calculated, and one-sided t-tests were performed with the null hypothesis that the classifiers 
trained with the actual mutation significance data were not more predictive than the classifiers 
trained with randomly-shuffled mutation significance data. 





, where ?̅? is the metric under consideration, 
calculated for the classifiers trained with actual mutation significance data, µ0is the mean of the 
metrics calculated for the classifiers trained with shuffled mutation significance data, σ is the 
standard deviation of the shuffled metrics, and n is the number of samples (in this case 10). P-
values were obtained for the one-sided significance tests with the Microsoft Excel function 
TDIST. 
 This permutation-based evaluation model is similar to the recursive feature selection 
algorithm utilized by Guo et. al for performing analysis of high-dimensional data.9 
 MutSig Power Evaluation 
 The randomly-shuffled mutation significance data from the previous power evaluation 
method were utilized for classifier training, but without the presence of the more predictive 
clinical data. Additionally, a second set of shuffled data was created, except the class labels for 
the examples were permuted instead of the mutation significance features. As before, classifiers 
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were trained on both the actual and permuted datasets, and statistical t-tests were performed 
similarly to the Clinical-MutSig power evaluation step. For this step, Glmnet models were not 
trained, as automated training and evaluation of this classifier for multiple datasets proved 
difficult due to the nature of the RWeka package. In addition, the Glmnet models had not proved 
especially effective at extracting predictive power from these data in previous evaluation steps. 
 
RESULTS 
 Result 1: Clinical-MutSig Evaluation 
 MLP RF Glmnet 
  Accuracy AUROC AUPRC Accuracy AUROC AUPRC Accuracy AUROC AUPRC 
Clinical 69.89% 0.717 0.745 70.45% 0.696 0.721 68.37% 0.687 0.711 
w/ MutSig 71.21% 0.717 0.738 69.89% 0.704 0.734 68.37% 0.687 0.712 
Table 1: Classifier performance with both Clinical and Clinical + MutSig feature sets. Baselines for each metric are 
as follows: Accuracy: 69.51%. AUROC: 0.500. AUPRC: 0.695. 
 
For the MLP and Glmnet classifiers, either no change or a decrease in predictive power 
metrics was observed with the addition of mutation significance data. With the RF classifier, a 
small increase in AUPRC was observed, though the statistical significance of this increase could 
not be confirmed. 
 Result 2: Clinical-MutSig Power Evaluation 
 MLP RF Glmnet 
 Accuracy AUROC AUPRC Accuracy AUROC AUPRC Accuracy AUROC AUPRC 
p-value < 5e-4 < 0.001 < 0.1 < 0.2 < 0.005 < 5e-4 > 0.2 < 0.025 < 0.1 
Table 2: Results of one-sided t-tests for each comparison metric, as described in “Clinical-MutSig Power 
Evaluation” in Methods. Highlighted entries are cases where p < 0.05. 
 
Significant differences were found in AUROC for RF, MLP, and Glmnet classifiers 
between the actual and shuffled data, with the actual mutation significance data performing 
better. Additionally, the real data showed significantly better performance in AUPRC for the RF 
classifier only. 
 Result 3: MutSig Power Evaluation 
 MLP RF 
  Accuracy AUROC AUPRC Accuracy AUROC AUPRC 
p (gene shuffle) < 2.5e-6 < 1e-5 < 5e-5 < 1e-4 < 2.5e-7 < 2.5e-6 
p (class shuffle) < 2.5e-6 < 2.5e-5 < 2.5e-5 < 5e-4 < 1e-4 < 2.5e-4 
Table 3: Results of one-sided t-test for each comparison metric, as described in “MutSig Power Evaluation” in 
Methods. Highlighted entries are cases where p < 0.05. 
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Significant differences were found in accuracy, AUPRC, and AUROC for both RF and 
MLP (Glmnet models were not trained for this evaluation). In both the case of within-feature 
shuffling and the case of class label shuffling, the actual mutation significance data outperformed 
the shuffled data much more clearly than in the previous evaluation which included clinical data 
features. 
DISCUSSION 
 The results in Table 1 show little to no improvement with the simple addition of the 
mutation significance features to the dataset. Glmnet, a method that automatically selects the 
most informative and non-correlative features, shows no change between the clinical and 
mutation significance-enriched datasets. This indicates that the clinical data may provide the 
same or much more predictive information than the MutSig data. To reduce the influence of the 
clinical features on the analysis, the power evaluations were performed. 
 In Table 2, results show that the mutation significance features are not devoid of 
predictive power, and the p-values for AUPRC and AUROC of the Random Forest classifier 
confirm the results of Guo et. al9 regarding the relative effectiveness of this classifier with class 
imbalance problems. This suggests that RF and/or other bagged classification methods may be 
good candidates for model building in this context. 
 The results of the third evaluation show even more clearly that predictive value exists in 
the mutation significance data. These results also confirm the conclusions reached about the 
relative information present in the clinical data compared to the mutation significance data. 
It is worth noting that in many cases, the MLP classifier tended to drastically overfit the 
data, often yielding training accuracies 20 percentage points higher than the testing accuracies. 
This would indicate that metrics obtained from MLP classifiers in this thesis may be misleading, 
and emphasizes the importance of parameter tuning during model training. The RF and Glmnet 
classifiers showed no such evidence of overfitting. 
 
CONCLUSION 
 Overall, it appears that the MutSig data as output by Broad’s Firehose analysis pipeline 
does have some predictive value when considering two-year survival of HNSC patients in 
TCGA. Results indicate that the information provided by these mutation significance data is 
either correlative with, or dwarfed by the information found in clinical features. Additionally, 
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results with the Random Forest classifier suggest that it or other bagged classifiers may be 
effective tools for this classification problem. 
 Though some predictive power has been found in the data, this approach is not one that 
can be directly extended to clinical environments. However, the presence of any predictive 
information suggests that further high-level or even variant-level analyses may prove effective in 
increasing predictive power.  
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Supplementary Table 1: List of clinical data features, including patient- and treatment-specific 
information. 
 
Age Alcohol consumption per day Anatomic Organ 
Ethnicity Laterality Lymphovascular Invasion 
Margin Status Tobacco Pack-Years Smoked Perineural Invasion 
Lymph Nodes Examined HPV Status (ISH) HPV Status (P16) 




Smokeless Tobacco Average 
per day 
Gender (sex) Race Tumor Grade 
Tobacco Smoking History History of Neoadjuvant Tx AJCC Clinical Nodes (CN) 
AJCC Clinical Metastasis 
(CM) 
AJCC Pathologic Metastasis 
(PM) 
AJCC Pathologic Tumor 
Stage  
AJCC Pathologic Tumor (PT) AJCC Clinical Tumor (CT) AJCC Clinical Tumor Stage 
Radiation Tx Adjuvant AJCC Pathologic Nodes (PN) Pharmaceutical Tx Adjuvant 
New Tumor Event Pharm Tx Pharmaceutical Therapy Adj. New Tumor Event Surgery 
New Tumor: Surgery 
Metastatic 




Radiation Total Dose New Tumor Event Rad Tx Definitive Tx Method 
RX: Therapy Type Radiation Therapy Type RX: Number of Cycles 











Supplementary Table 2: List of genes for which mutation significance was considered. The ten 
most-populated genes were chosen from the MutSig2CV output. All gene features other 
than TP53 were considered too sparsely-populated for informative categorical distinction 
(77%-93% with “no mutation”), and as such were collapsed into binary variables 
(“mutation” or “no mutation”) to prevent overfitting. The TP53 mutation significance 
feature itself exhibits a distribution within which individual categories are relatively well-
populated, with only 32% of examples having “no mutation”. 
 
TP53 FAT1 
CDKN2A NOTCH1 
PIK3CA MLL2 
NSD1 CASP8 
HUWE1 THSD7A 
 
